Artiva Biotherapeutics Inc. announced positive initial safety and translational data from ongoing clinical trials of AlloNK (AB-101), an allogeneic, off-the-shelf natural killer (NK) cell therapy, in combination with rituximab or obinutuzumab for the treatment of autoimmune diseases. The results, which were presented during a company webcast, indicate that AlloNK was generally well tolerated and demonstrated deep B-cell depletion in outpatient and community settings. Artiva remains on track to share initial clinical response data and conduct regulatory interactions with the U.S. Food and Drug Administration (FDA) to align on the pivotal trial design for AlloNK in refractory rheumatoid arthritis $(RA)$ in the first half of 2026.